Premium
Combined malonic and methylmalonic aciduria due to ACSF3 mutations: Benign clinical course in an unselected cohort
Author(s) -
Levtova Alina,
Waters Paula J.,
Buhas Daniela,
Lévesque Sébastien,
AurayBlais Christiane,
Clarke Joe T.R.,
Laframboise Rachel,
Maranda Bruno,
Mitchell Grant A.,
BrunelGuitton Catherine,
Braverman Nancy E.
Publication year - 2019
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1002/jimd.12032
Subject(s) - methylmalonic acid , methylmalonic aciduria , newborn screening , medicine , cohort , gastroenterology , urine , creatinine , pediatrics , genotyping , retrospective cohort study , malonic acid , cohort study , genotype , genetics , biology , biochemistry , gene , vitamin b12
Abstract Background The clinical significance of combined malonic and methylmalonic aciduria due to ACSF3 deficiency (CMAMMA) is controversial. In most publications, affected patients were identified during the investigation of various complaints. Methods Using a cross‐sectional multicenter retrospective natural history study, we describe the course of all known CMAMMA individuals in the province of Quebec. Results We identified 25 CMAMMA patients (6 months to 30 years old) with a favorable outcome regardless of treatment. All but one came to clinical attention through the Provincial Neonatal Urine Screening Program (screening on day 21 of life). Median methylmalonic acid (MMA) levels ranged from 107 to 857 mmol/mol creatinine in urine (<10) and from 8 to 42 μmol/L in plasma (<0.4); median urine malonic acid (MA) levels ranged from 9 to 280 mmol/mol creatinine (<5). MMA was consistently higher than MA. These findings are comparable to those previously reported in CMAMMA. Causal ACSF3 mutations were identified in all patients for whom genotyping was performed (76% of cases). The most common ACSF3 mutations in our cohort were c.1075G > A (p.E359K) and c.1672C > T (p.R558W), representing 38.2 and 20.6% of alleles in genotyped families, respectively; we also report several novel mutations. Conclusion Because our province still performs urine newborn screening, our patient cohort is the only one free of selection bias. Therefore, the favorable clinical course observed suggests that CMAMMA is probably a benign condition, although we cannot exclude the possibility that a small minority of patients may present symptoms attributable to CMAMMA, perhaps as a result of interactions with other genetic or environmental factors.